What Is Cardiovascular Competitive Intelligence?

Published November 4, 2026

Cardiovascular competitive intelligence (CI) is the routine work of finding, checking and interpreting public information about rival drugs, devices and trials in heart, vascular and metabolic disease, so that a company, a research group or an investor can make better decisions. It is closer to careful reporting than to forecasting, and in a field where one trial result can reset an entire drug class, the checking matters as much as the finding.

Updated November 4, 2026.

Who uses cardiovascular competitive intelligence?

The main users are business development and strategy teams at drug makers, clinical development and medical affairs groups that need to know what is being tested against them, and market-access teams. Contract research organizations use it to find sponsors and trial gaps, and academic centers and investors use it to see where money and patients are going. Pharmacists, students and curious readers use the same public sources, which is why this site writes in plain language.

What does it cover?

Pipelines: which assets exist, at what phase, and who owns them. See, for example, our notes on factor XI inhibitors.
Trials: design, size, comparator, endpoints and timing, usually from registry records. Our guide on reading a ClinicalTrials.gov record covers the basics.
Regulatory actions: filings, approvals and label changes in the US, EU, China and elsewhere.
Conferences: where results first appear in full. See our guide to covering ACC, ESC and AHA.
Commercial and market-access signals: company sales reports, pricing and reimbursement decisions, launch timing.

How is it different from market research?

Market research usually asks how big a market is and what customers or prescribers think, often through surveys and interviews. Competitive intelligence asks what competitors are doing and what has changed this week. In practice the two overlap, but CI leans on public documents (registries, regulators, company filings, society programs, journals) and is judged on whether each fact is correct, dated and sourced.

What does good output look like?

Good CI states the fact, the date and the source, separates what a company said from what has been published, and says what is still unknown. A good note on a topline press release tells the reader that the primary endpoint was or was not met, and that detailed numbers were not yet public if that is the case. It avoids ranking drugs on numbers from different trials and ends with what to watch next, with dates only where a source gives them.

A useful habit is a short change log: what is new since the last review, which source shows it, and how confident the analyst is. Readers can then see at a glance whether a line comes from a regulator, a registry record, a company statement or trade press, and judge it accordingly. Where a date or number could not be confirmed, a good note says so plainly rather than filling the gap.

What goes wrong? Four pitfalls, with 2026 examples

Press release versus paper. On September 4, 2026, Novartis announced that the Phase III Lp(a)HORIZON trial of pelacarsen did not meet its primary endpoint, although pelacarsen lowered Lp(a), and said the full data would be presented at an upcoming congress (Novartis). The release gave no size of Lp(a) reduction and no safety data. TCTMD’s preview of AHA 2026 lists Lp(a)HORIZON for presentation in full on Saturday, November 7 (TCTMD). Until then, anything beyond the headline is guesswork. Our pelacarsen note tracks this.

Mixing up similar assets. LIBREXIA-ACS is a trial of milvexian, not asundexian. It was presented at ESC Congress 2026 in Munich on August 29 and published in the New England Journal of Medicine. Among 14,194 patients the primary endpoint occurred in 5.4% on milvexian and 5.1% on placebo (hazard ratio 1.05; 95% CI 0.91 to 1.21), with intracranial or fatal bleeding in 0.3% of each group; the trial had been stopped for futility in November 2025 (News-Medical, summarizing the ESC release). Asundexian is a different factor XIa inhibitor, from Bayer. On October 26, 2026, pharmaphorum reported that it had been approved in China under the brand name Sunharbo, for reducing the risk of a second stroke after a non-cardioembolic ischemic stroke or high-risk transient ischemic attack, based on OCEANIC-STROKE (pharmaphorum). A CI note that blurs the two compounds, or the two settings (stroke versus acute coronary syndrome), would mislead.

Renames and code names. Registry records often use development codes. ClinicalTrials.gov titles for finerenone studies use “BAY94-8862”, and Boehringer Ingelheim’s vicadrostat appears as “BI 690517” (HCPLive). Searching only the brand or generic name misses records.

Stale registry records. Boehringer Ingelheim announced on September 15, 2026 that it was discontinuing EASi-KIDNEY after an independent monitoring committee judged that adding vicadrostat to empagliflozin was unlikely to improve the primary endpoint (HCPLive). When we queried the ClinicalTrials.gov API on November 4, the EASi-KIDNEY record (NCT06531824) still showed “Active, not recruiting” with an estimated primary completion of December 2026 (ClinicalTrials.gov). Registry dates are estimates and lag events, so they should be cross-checked against company news.

Cross-trial comparisons. Hazard ratios from trials with different patients, endpoints and follow-up are not interchangeable. For instance, SPIRIT-HF (spironolactone, 730 patients, presented at ACC 2026) and FINEARTS-HF (finerenone, 6,001 patients) both studied heart failure with mildly reduced or preserved ejection fraction, yet differ in size, design and follow-up, and SPIRIT-HF’s investigators described it as underpowered (TCTMD). See our finerenone landscape for how we handle this.

Next step

Want help applying this to the cardiovascular and metabolic areas you compete in? Request information and we will share sample deliverables.

This article is for informational and competitive-intelligence purposes only and is not medical advice. Approvals, labels and trial results change; verify details against current prescribing information and primary sources.